EVM
MDGL icon

Eaton Vance Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Eaton Vance Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-45
Closed -$5K – 2938
2021
Q1 		$5K Buy
+45
New +$5.25K ﹤0.01% 2601

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Eaton Vance Management's MDGL Position: Q2 2021 in Review

Eaton Vance Management sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2021, closing a stake of 45 shares — an estimated $5K sold.

Eaton Vance Management first reported a position in MDGL in Q1 2021 and held it in 1 quarter. The position peaked at $5K in Q1 2021. 151 funds tracked by Wall St. Rank hold MDGL as of Q2 2021.

  • Eaton Vance Management reported no remaining Madrigal Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Eaton Vance Management sold 45 Madrigal Pharmaceuticals shares in Q2 2021, an estimated $5K.
  • Eaton Vance Management first reported a position in Madrigal Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Eaton Vance Management's Madrigal Pharmaceuticals position peaked at $5K in Q1 2021.
  • 151 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2021.

Based on Eaton Vance Management's 13F filing for Q2 2021, filed 16 Aug 2021.